Fig. 1.

Anti-MOG + C-mediated demyelination. a The left top panel shows a schematic drawing of the experimental setup showing how demyelination was quantified. The degree of demyelination in percentage was measured as the loss of myelin (area of myelin loss) divided by area of corpus callosum (CC area) in that hemisphere of the brain. The right top panel shows a dose response for demyelination in CC of C57BL/6 mice receiving purified monoclonal anti-MOG antibody from hybridoma clone Z2, along with C. Data are shown as mean ± SEM, the total number of animals in each group is shown underneath columns, and this experiment was repeated only a single time with each dose. b Representative images of LFB and C9neo staining from C57BL/6 mice injected with anti-MOG, control IgG2a+C and anti-MOG + C. Magnification: LFB (×4 and ×20) and C9neo (×20). c Quantitation of the area of myelin loss in CC in C57BL/6 mice 2 days after injection of anti-MOG, control IgG2a+C, and anti-MOG + C as well as NOD-Scid/J immunodeficient mice injected with anti-MOG + C and pathology. Statistical significance was assessed using two-tailed Mann–Whitney U test. Results are shown as mean ± SEM, the total number of animals in each group is shown underneath columns. This experiment was repeated at least three times